[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"$AKESF $SMMT $ONC $MRK ESMO 2025: Akeso Summit's ivonescimab beats PD-1 in first chemo combo win in first-line NSCLC - Ivonescimab and chemo reduced the risk of progression or death by XX% compared with BeOnes Tevimbra and chemo in first-line squamous NSCLC"
X Link @MarcJacksonLA 2025-10-19T16:10Z 7583 followers, XXX engagements
"$SMMT $AKESF ESMO 2025: Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by XX% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China Ivonescimab in Combination with Chemotherapy Is the First Known Regimen to Achieve a Clinically Meaningful Benefit over an anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase X Clinical Trial in 1L NSCLC: Median PFS of XXXXX Months vs. XXXX Months Respectively for Patients Receiving Ivonescimab Plus Chemotherapy vs."
X Link @MarcJacksonLA 2025-10-19T15:18Z 7583 followers, 1853 engagements
"$SMMT $AKESF HARMONi-6 Still Chinese data still impressive now in first line NSCLC against Tislelizumab. Still no OS "
X Link @PersimmonTI 2025-10-19T15:08Z 10.3K followers, 4703 engagements
"$AKESF $SMMT Choosing China: Akesos $3M Beginnings and the Rise of Chinas Biotech Sector"
X Link @MarcJacksonLA 2025-09-18T15:31Z 7577 followers, XXX engagements